Richiedi una copia del documento: Proprotein convertase Subtilisin-Kexin type 9 (PCSK9) inhibitors and cardiovascular risk: does a further analysis of the fourier trial suggest changes in the target of lipid lowering therapy?

Captcha code
Annulla